About: The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19
Creator	Lohmer, R Schmith, Ginny Schmith, Virginia Zhou, Jessie
source	MedRxiv
abstract	Introduction: Caly, Druce (1) reported that ivermectin inhibited SARS-CoV-2 in vitro for up to 48 h using ivermectin at 5 uM. The concentration resulting in 50% inhibition (IC50, 2 uM) was >35x higher than the maximum plasma concentration (Cmax) after oral administration of the approved dose of ivermectin when given fasted. Method: Simulations were conducted using an available population pharmacokinetic model to predict total (bound and unbound) and unbound plasma concentration-time profiles after a single and repeat fasted administration of the approved dose of ivermectin (200 ug/kg), 60 mg, and 120 mg. Plasma total Cmax was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung Cmax after administration of each single dose. Results: Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC50, even for a dose level 10x higher than the approved dose. Even with higher exposure in lungs than plasma, ivermectin is unlikely to reach the IC50 in lungs after single oral administration of the approved dose (predicted lung: 0.0857 uM) or at doses 10x higher that the approved dose administered orally (predicted lung: 0.817 uM). Conclusions: The likelihood of a successful clinical trial using the approved dose of ivermectin is low. Combination therapy should be evaluated in vitro. Re-purposing drugs for use in COVID-19 treatment is an ideal strategy but is only feasible when product safety has been established and experiments of re-purposed drugs are conducted at clinically relevant concentrations.
has issue date	2020-04-26(xsd:dateTime)
bibo:doi	10.1101/2020.04.21.20073262
has license	medrxiv
sha1sum (hex)	4f99831cb29dcc18c2d883fb7b0a75b3b7b2f973
schema:url	https://doi.org/10.1101/2020.04.21.20073262
resource representing a document's title	The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19
resource representing a document's body	covid:4f99831cb29dcc18c2d883fb7b0a75b3b7b2f973#body_text
is schema:about of	named entity 'ivermectin' named entity 'oral administration' named entity 'Introduction' named entity 'CALY' named entity 'INHIBITED' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software